Hookipa stock surges 46% on license deal with Roche for immunotherapy
seekingalpha.com
finance
2022-10-20 11:56:22

Rafael_Wiedenmeier/iStock Unreleased via Getty Images Roche (OTCQX:RHHBY) (OTCQX:RHHBF) signed a license agreement with Hookipa Pharma (NASDAQ:HOOK) to develop immunotherapy HB-700 for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy. Under the agreement, Hookipa will receive $25M upfront. The Swiss pharma giant will have the option for an another product candidate, in which case Hookipa will get an additional $15M at option exercise. Including this option payment, Hookipa is eligible for research, development and commercialization milestone-based payments for HB-700 and the additional candidate for up to ~$930M, plus royalties on net sales, the New York-based company said in a press release on Thursday.
